A Calculated Move: Putting Environmental Assessment Data to Wider Use
Cristin Konkart and Shawn James investigate the importance of the underlying methodologies and expertise behind product carbon footprints and lifecycle assessments, drawing on Ypsomed’s accrued organisational expertise to demonstrate how these processes are evolving and providing greater value to the company and its partners.
Across the medical device and pharmaceutical industries, the need for reliable environmental data is growing. Pharmaceutical companies increasingly require information from across their supply chains to understand the carbon footprint of their products and support their own sustainability reporting and targets. Device manufacturers therefore need to provide robust, product-specific carbon-footprint information. Product Carbon Footprint (PCF) assessments provide this information by quantifying the greenhouse gas emissions associated with a product. The resulting PCF figure, however, is only as robust and useful as the data, methodology and expertise behind it.
Ypsomed has been conducting PCF assessments since 2020, building practical experience, established processes and internal expertise. Its current assessments focus on CO2 emissions, while full Life Cycle Assessments (LCAs) consider a broader range of environmental impact categories. As standards and regulatory expectations evolve, this established competence provides an important foundation for expanding life-cycle thinking.
Combined with expertise across the organisation and Ypsomed’s active participation in industry consortia, this accumulated experience enables more rigorous assessment of environmental impacts and contributes to the development of evolving methodologies and standards. Increasingly, that competence also creates opportunities to bring environmental assessment further upstream into product development, while design choices can still be influenced.